Medical Science Liaison II, Great Plains

Job description

We’re looking for a highly skilled Medical Science Liaison II (MSL II) to serve as a field-based scientific expert within oncology. In this role, you will build and maintain credible, peer-to-peer relationships with key opinion leaders (KOLs), clinical investigators, and healthcare professionals, while providing balanced, evidence-based information on our investigational and marketed therapies. You’ll play a critical role in gathering clinical insights, supporting research, and ensuring our scientific communications are accurate, compliant, and strategically aligned. Key Responsibilities Engage with KOLs and external experts to discuss clinical data, emerging research, and disease-state insights Support investigator-initiated and company-sponsored studies and represent the company at scientific meetings and congresses Deliver clear, balanced scientific presentations and communicate field insights to internal stakeholders Summarize key scientific updates and competitive intelligence to inform medical strategy and evidence-generation plans Collaborate cross-functionally with Medical Affairs, Clinical Development, Regulatory, and Commercial teams to support clinical trial feasibility, investigator identification, and educational initiatives Ensure all activities comply with SOPs, PhRMA Code, and global regulatory requirements while staying current on evolving oncology research Contribute to internal training, medical planning, and continuous improvement of field processes Advanced scientific degree (PharmD, PhD, MD, or equivalent) Minimum 10 years of pharma/biotech experience, including at least 3 years as an MSL or in a field medical role Strong understanding of oncology disease states and emerging therapies Excellent communication, presentation, and interpersonal skills Ability to distill complex scientific data into clear, actionable insights Deciphera is committed to fair and equitable compensation practices. The base salary pay range for this role is $192,800 - $264,000. Actual compensation packages will depend on various factors, including, but not limited to depth of experience, education, skillset, overall performance and/or location.​ Deciphera believes in providing a competitive compensation and benefits package to all employees. Our base salary is just one component of Deciphera’s competitive total rewards strategy that also includes annual performance bonus, a long-term incentive plan, full range of benefits and other incentive compensation plans (if applicable) Benefits: Competitive salary and annual bonus. Comprehensive benefits package including medical, dental, vision insurance, 401(k) retirement plan with company match, and more. Generous parental leave and family planning benefits. Outstanding culture and opportunities for personal and professional growth. EQUAL EMPLOYMENT OPPORTUNITY INFORMATION Deciphera is committed to equal employment opportunity and values diversity. To ensure that we comply with reporting requirements, we invite you complete the confidential survey at the end of this application. Providing this information is optional. It will not be accessible or used in the hiring process, and has no effect on your opportunity for employment. This information will also be treated confidentially. We are committed to make all hiring decisions and other employment decisions on a non-discriminatory basis. Deciphera, a member of Ono Pharmaceutical Co., Ltd., is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines and providing hope to people living with cancer, neurologic and autoimmune disease. Deciphera is leveraging its proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from Deciphera’s platform in clinical studies, QINLOCK® (ripretinib) is Deciphera’s switch-control kinase inhibitor approved in many countries including the European Union and the United States for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib. ROMVIMZA® (vimseltinib) is a kinase inhibitor approved in the United States for adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause worsening functional limitation or severe morbidity, and in the European Union for adult patients with TGCT associated with clinically relevant physical function deterioration and in whom surgical options have been exhausted or would induce unacceptable morbidity or disability. The spirit of collaboration that has brought medications to life continues to guide how we operate, grow, and discover new breakthroughs. We cultivate an inclusive culture that values curiosity, creativity, and shared accountability—empowering individuals to challenge the unknown together. Deciphera offers competitive compensation, including equity-based compensation, and a comprehensive benefits package that includes medical, dental, vision, 401(k) retirement plan, life insurance and a flexible spending account for either health care and/or dependent care.